Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Newly available and recent advances in drug-eluting stents.

Expert review of cardiovascular therapy·2013

Same author

Reply: To PMID 23257375.

JACC. Cardiovascular interventions·2013

Same author

Can bioabsorbable scaffolds be used in calcified lesions?

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2013

Same author

Impact of residual chronic total occlusion of right coronary artery on the long-term outcome in patients treated for unprotected left main disease: the Milan and New-Tokyo registry.

Circulation. Cardiovascular interventions·2013

Same author

[Intra-arterial thrombolysis facilitated by ultrasound in submassive pulmonary embolism: first documented case report in Italy].

Giornale italiano di cardiologia (2006)·2013

Same author

Renal denervation in a patient with two renal accessory arteries: a case report.

Blood pressure·2013

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Published on: January 21, 2020

Paclitaxel-eluting stents.

John Cosgrave¹, Simon Corbett, Rade Babic

¹EMO Centro Cuore Columbus & San Raffaele Hospital, Milan, Italy.

Future Cardiology

|October 7, 2009

Summary

This summary is machine-generated.

Paclitaxel-eluting stents are crucial for preventing restenosis after percutaneous coronary intervention. This review examines current paclitaxel stent trials and future directions for this vital revascularization therapy.

More Related Videos

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Related Experiment Videos

Last Updated: Jun 19, 2026

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Published on: January 21, 2020

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Area of Science:

Cardiovascular Medicine
Interventional Cardiology
Biomedical Engineering

Background:

Percutaneous coronary intervention (PCI) and stent implantation are primary revascularization methods.
Restenosis, driven by smooth muscle cell proliferation, limits long-term PCI success.
Existing treatments have shown limited efficacy in preventing restenosis.

Purpose of the Study:

To review clinical trial outcomes of current paclitaxel-eluting stents (PES).
To discuss ongoing research and future advancements in PES technology.
To highlight paclitaxel's role in mitigating restenosis post-PCI.

Main Methods:

Systematic review of published clinical trials on paclitaxel-eluting stents.
Analysis of efficacy and safety data from key PES studies.
Evaluation of emerging stent platforms and drug-eluting technologies.

Main Results:

Paclitaxel-eluting stents have demonstrated significant reductions in restenosis rates compared to bare-metal stents.
Various stent platforms show comparable efficacy, with ongoing research focusing on optimizing drug delivery and polymer coatings.
Long-term data continues to support the benefit of PES in reducing repeat revascularization procedures.

Conclusions:

Paclitaxel-eluting stents are a cornerstone therapy for preventing restenosis after PCI.
Continued innovation in stent design and drug-eluting technology promises further improvements in patient outcomes.
Future research should focus on personalized treatment strategies and long-term safety profiles of advanced PES.